Evidence map›Paper›PMID 41011782›Full record

ArticlePathogens (Basel, Switzerland)2025

Zinc Acetate Inhibits Hepatitis A Virus Replication: Possible Treatment for Patients with Type A Acute-on-Chronic Liver Failure.

Tatsuo Kanda, Reina Sasaki-Tanaka, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Kazunao Hayashi, Hiroteru Kamimura, Atsunori Tsuchiya, Ryota Masuzaki, Hirofumi Kogure and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tatsuo KandaDivision of Gastroenterology and Hepatology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Uonuma Kikan Hospital, 4132 Urasa, Minami-Uonuma 949-7302, Japan.ORCID 0009-0000-8135-342X
Reina Sasaki-TanakaDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Aasahimachi-Dori, Chuo-ku, Niigata 951-8520, Japan.
Hiroyuki AbeDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Aasahimachi-Dori, Chuo-ku, Niigata 951-8520, Japan.ORCID 0000-0003-2618-7494
Takeshi YokooDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Aasahimachi-Dori, Chuo-ku, Niigata 951-8520, Japan.ORCID 0000-0001-7138-1785
Akira SakamakiDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Aasahimachi-Dori, Chuo-ku, Niigata 951-8520, Japan.
Kazunao HayashiDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Aasahimachi-Dori, Chuo-ku, Niigata 951-8520, Japan.ORCID 0000-0003-3764-3598
Hiroteru KamimuraDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Aasahimachi-Dori, Chuo-ku, Niigata 951-8520, Japan.ORCID 0000-0002-9135-3092
Atsunori TsuchiyaDepartment of Gastroenterology and Hepatology, Faculty of Medicine, University of Yamanashi, Chuo 409-3898, Japan.
Ryota MasuzakiDivision of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kamicho, Itabashi-ku, Tokyo 173-8610, Japan.ORCID 0000-0001-5118-4397
Hirofumi KogureDivision of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kamicho, Itabashi-ku, Tokyo 173-8610, Japan.ORCID 0000-0002-2355-7309
Hiroaki OkamotoDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan.ORCID 0000-0003-0827-0964
Shuji TeraiDivision of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-757 Aasahimachi-Dori, Chuo-ku, Niigata 951-8520, Japan.ORCID 0000-0002-5439-635X

Funding

Japan Agency for Medical Research and Development JP24fk0210132Japan Agency for Medical Research and Development JP25fk0210132
6 · The paper itself

Abstract

Hepatitis A virus (HAV) infection sometimes results in the occurrence of acute liver failure and acute-on-chronic liver failure (ACLF), which is often fatal, especially in patients with diabetes mellitus or elderly individuals. ACLF is observed in patients with cirrhosis who occasionally have zinc deficiency. However, effective drugs for hepatitis A are currently unavailable. Glucose-regulated protein 78 (GRP78) is an antiviral agent that has been reported to prevent HAV replication. The effects of zinc acetate on HAV HA11-1299 genotype IIIA replication and changes in GRP78 levels in human hepatocytes with or without HAV infection were examined. Zinc acetate inhibited HAV HA11-1299 genotype IIIA replication in both Huh7 and GL37 cells. Zinc acetate also inhibited HAV replication in both low- and high-glucose media. Zinc acetate increased the expression of GRP78, in response to HAV replication. The combination of zinc acetate with ribavirin led to greater suppression of both HAV HA11-1299 genotype IIIA and HAV HM175/18f genotype IB replication in Huh7 cells than that of ribavirin alone. In conclusion, zinc acetate inhibits HAV replication in accompany with the elevation of GRP78 expression without causing cellular toxicity. Zinc compounds may be useful for the treatment of ACLF caused by HAV infection.

Indexed as

Acute-On-Chronic Liver FailureAntiviral AgentsHepatitis AHepatitis A virusVirus ReplicationZinc AcetateCell LineEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHepatocytesHumansAntiviral AgentsEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHSPA5 protein, humanZinc Acetateantiviralglucose-regulated protein 78hepatitis A virusribavirinzinc acetate

Identifiers

PMID41011782
PMCPMC12472899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.